Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials

D Thaçi, D Jullien, A Egeberg, J M Carrascosa, J J Wu, I Pau-Charles, P Gisondi

Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology : JEADV
Issue number11
Pages (from-to)e709-e711
Publication statusPublished - 11.2021

Cite this